Prolia - Meaningful BMD Gains | Osteoporosis | Amgen

PROLIA® IS ASSOCIATED WITH A HIGH RESPONSE RATE OF CLINICALLY MEANINGFUL BMD GAINS AT KEY SKELETAL SITES1

In a sub-study of FREEDOM, across 19 of the 213 study centres with capabilities to perform BMD analyses using DXA, more frequent BMD assessment and evaluation of additional skeletal sites were performed in 441 patients.1
The results show that Prolia® significantly improved BMD at key skeletal sites vs placebo as early as 1 month.1 In addition, after 3 years of Prolia® treatment:
Clinically meaningful BMD gains at lumbar spine and total hip after receiving Prolia.
Clinically meaningful gains were determined as increases in bone mineral density above the least significant change of more than 3% at 36 months. For lumbar spine, this was 90%, and for total hip, this was 74%. Data are from the FREEDOM study and extension in which women were randomized to receive either Prolia® 60 mg or placebo subcutaneously every 6 months. Spine and hip DXA BMD responses are from the overall study (n=7,808) and a sub-study of 441 women in which more extensive assessments were evaluated.1

References:
BMD: bone mineral density; DXA: dual x-ray absorptiometry.
  1. Bolognese MA, et al. J Clin Densitom. 2013;16:147–53.

SMPC

The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public